U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06926790) titled 'Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)' on March 30.
Brief Summary: Neoadjuvant immunotherapy followed by surgery has emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, conventional chemotherapy components may increase treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1 expression <1% remains to be improved. Emerging evidence has demonstrated that the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) provides superior response...